{"id":"W2952182954","doi":"10.1136/annrheumdis-2019-eular.3083","title":"FRI0171 CLINICAL RESPONSES IN PATIENTS WITH INADEQUATE RESPONSE TO BDMARDS UPON TREATMENT WITH UPADACITINIB","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Research Manitoba","funders":"Regeneron Pharmaceuticals; Gilead Sciences; AbbVie; Sanofi; Amgen; Pfizer; Samsung; Genentech; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Rheumatoid arthritis; Internal medicine; Placebo; Adverse effect; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009406019,0.0002906822,0.0007205407,0.0004623459,0.0003004459,0.0008058913,0.0003516451,0.0003906366,0.002898258],"category_scores_gemma":[0.001880557,0.0001113432,0.0005621936,0.0004408573,0.0002529305,0.0004170935,0.0002901075,0.0007811148,0.0006084411],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001020807,"about_ca_system_score_gemma":0.0005788716,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001407151,"about_ca_topic_score_gemma":0.003274996,"domain_scores_codex":[0.9994554,0.00009953688,0.00006965076,0.00009739854,0.0001207029,0.00015731],"domain_scores_gemma":[0.9990839,0.0002467138,0.0002941804,0.00004365423,0.0001229947,0.0002086],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.04958012,0.0005830072,0.6717846,0.0007997238,0.001369131,0.004449694,0.0002957775,0.00110624,0.03445902,0.0006395773,0.01439751,0.2205357],"study_design_scores_gemma":[0.001708302,0.005522691,0.9427767,0.0002334825,0.001036963,0.01384467,0.0005973731,0.001800255,0.007545212,0.00054889,0.02428791,0.00009764975],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.978048,0.008923122,0.0004249749,0.0008955833,0.0001915577,0.00009210507,0.002669281,0.00008368511,0.008671628],"genre_scores_gemma":[0.9954177,0.0007525944,0.0002991653,0.0003402132,0.0000587735,0.00003570523,0.002137443,0.00001194302,0.0009464834],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002898258,"threshold_uncertainty_score":0.00969559,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04816730546240868,"score_gpt":0.3694457898233973,"score_spread":0.3212784843609887,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}